Loading company…
Boston-based biopharmaceutical company developing drugs for rare immune system disorders and rare cancers.
Established in 2012 and based in Boston, Massachusetts, X4 Pharmaceuticals develops and markets drugs for immune system dysfunction disorders, with a research center in Vienna, Austria. In March 2019 it merged with Arsanis, Inc., and the combined company trades on the Nasdaq Capital Market as XFOR. In May 2023, New Enterprise Associates, Bain Capital and other investors agreed to acquire the company for USD 65 million; its listed stage is Public.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in